TT-20
/ Tellus Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 22, 2025
A First in Human, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of TT20 Administered Intravenously as Single Dose Infusions and Continuous Infusions in Healthy Adult Volunteers
(ANZCTR)
- P1 | N=72 | Not yet recruiting | Sponsor: Tellus Therapeutics
New P1 trial • CNS Disorders • Vascular Neurology
1 to 1
Of
1
Go to page
1